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INTRODUCTION 
Transformed migraine is one of the subtypes of chronic daily headache (CDH), and is similar to 
chronic migraine, described in the new International Headache Society (IHS) classification 
2004.1 The term CDH refers to the Headache disorders experienced 15 or more days a month and 
includes headaches associated with medication overuse.2,3 CDH can be divided into primary and 
secondary varieties. Primary CDH is not related to a structural or systemic illness. It includes 
diseases such as Transformed migraine (TM). Chronic tension-type headache (CTTH), new daily 
persistent headache (NDPH), and hemicrania continua (HC). Secondary CDH has an identifiable 
underlying cause, including post-traumatic headache, cervical spine disorders, vascular 
disorders, nonvascular intracranial disorders and headaches associated with temporomandibular 
joint disorders, sinus infections, chronic meningitis, low and high intracranial pressure. In this 
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study we have adopted the 1996 definition of TM proposed by Silberstein and Lipton in 
preference to the new discredited 2004 IHS criteria for chronic migraine.  
 The association between migraine and psychiatric disorders has long been established. 
Several clinic-based4-6 and population-based7-9 studies have discussed the relationship. However 
psychiatric comorbidity in transformed migraine has seldom been discussed, and the effect on 
overall outcome has not been examined . Population based studies have shown that 4% to 5% of 
the general population has primary CDH.10 Transformed migraine is the major cause of CDH 
and is associated with poor quality of life and greater medical and social expenses compared to 
episodic migraine.11,12 CDH is most commonly transformed Migraine and is accompanied by 
high anxiety levels in most patients and with hysterical traits in some. These patients frequently 
have a coexisting depressive disorder.12 The purpose of this study is to characterize psychiatric 
disorders accompanying TM in a tertiary headache center and to examine their impact on 
outcome.  
 
Patients and Methods 
One hundred and thirty nine consecutive patients of Transformed Migraine (Defined by 
Silberstein Lipton criteria) attending a quaternary headache center were offered entry into the 
study. Their headache history was taken by a neurologist. Each patient had a diagnostic semi 
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structured psychiatric interview by a psychiatrist or psychologist, a Beck Depression Inventory 
(BDI), Migraine Disability Assessment Score (MIDAS), and a SF-36. 
 At 3, 6, and 12 months, headache frequency, intensity scores, BDI, MIDAS, and SF-36 
scores were measured. MIDAS and SF-36 have been validated in previous headache studies and 
are sensitive to clinical change.13,14 The BDI is a standardized test and also validated to diagnose 
the presence of depression. 
The headache severity index  was calculated by multiplying number of days with baseline 
headache by the baseline intensity and adding  the number of days with a headache exacerbation 
multiplied by the exacerbation intensity and divided by 30 days. The data was then analyzed 
using SAS and regression analysis. 
 
 
RESULTS 
Overall 82 subjects consented to the study. 69 were women (84%) and 13 were men (16%). With 
a mean age of  39.7±13.2 years. The mean age of onset of episodic migraine was 18.6±11.5 years 
and mean duration of daily headache was 7.0±8.0 years. Aura was present in 23 patients (28%)  
(16 visual, 1 sensory, and 6 mixed).  86.6%(71 Pts) of the study population over used acute 
treatment, with a mean duration of overuse of 4.3±5.4 years. The mean initial headache 
frequency was 23.2±6.1 days. At twelve months, the mean headache frequency decreased to 
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13.4±11.1 days. The mean initial baseline headache intensity was 5.7±2.0 out of 10, at twelve 
months, the mean baseline headache intensity decreased to 5.1±1.9. The baseline mean 
exacerbation headache frequency and intensity was 6.2±5.9 and 7.8±3.4, respectively. At twelve 
months the mean exacerbation headache frequency and intensity decreased to 4.0±4.2 and 
7.6±1.8 respectively. The headache severity index was 6.5±1.5 at headache onset and 4.5±2.5 at 
12 months (p<0.0001 for difference, Dunnett’s method for multiple comparisons. 
We classified the 82 patients enrolled in the study into three categories of response to treatment, 
high, intermediate and low. High response was defined as a decrease in headache severity of 4.73 
or greater. Intermediate response, based on severity change between 0.83 and 4.73 and low 
response, based on severity changes less then 0.83 on the 11 point VAS scale. Based on this  
response criteria 29 subjects had a high response, 36 an intermediate response and 17 a low 
response (Figure 1). Age can not predict outcome as patients with young age showed both type 
of response, high as well as low and patients with middle age group had intermediate response 
(Figure 2). 
The highest change in headache severity index occurs with patients who had worst headache 
score at baseline, showed by Kruskal-Wallis test for non-parametric analysis. (Figure 3). The 
Beck Depression Inventory (BDI) scores varied widely with an initial range of 0-44, and it 
decreased gradually between six months but slightly increased at 12 months but all were still less 
than at baseline. (Figure 4). Patients with low BDI score at baseline had a good outcome (Figure 
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5). SF-36 results showed a varied response among its various sub-categories and was not a good 
predictor of outcome but was a good measurement of outcome.( Figure 6 ). The MIDAS scores 
were predominantly in Grade IV with 78% (n=58) scoring greater than 21 at the initial 
evaluation. A number of subjects improved to a Grade I-III at 3 and 6 months (Figures 7). 
Most patients had psychiatric comorbidity, seventy-two patients (88%) had at least one Axis I 
diagnosis. The most common diagnostic groups were Adjustment Disorder (n=35), Depression 
(n=22), and Generalized Anxiety Disorder GAD (n=14) (Figure 8). In utilizing 3 categories of 
high/intermediate/low response, patients with Adjustment disorder showed low response in 55% 
of cases as compared to 38% in each of high and lintermediate response categories. 17% of 
Depressed patients showed high response, 33% intermediate and 18% low response. 11% of 
GAD patients showed high response, 18% intermediate and 12% low response, as compared to 
patients with no Axis 1 psychiatric disorder 22% showed high response, 8% intermediate and 6% 
low response. 
 
 
DISCUSSION 
On Transformed Migraine patients had severe disability which profoundly affected their function 
and quality of life. Patients improved with treatment but still had significant pain, disability, and 
poor quality of life. 
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For chronic migraine (CM) the requirement that the daily headache must meet the criteria for 
migraine without aura each day remains a concern with the first revision of the new proposed 
IHS criteria, which captures only a small number of patients with TM, as even episodic migraine 
does not always meet IHS migraine criteria throughout the attack.1 For that reason we adopted 
Silberstein and Lipton revised Criteria for transformed migraine, stating that patients should have 
daily or almost daily (≥15 d/mon) head pain for ≥ 1 month with average headache duration ≥4 
h/day with at least one of the following 1) history of episodic migraine meeting an IHS criteria 
1.1 to 1.6. 2) history of increasing Headache frequency with decreasing severity of migrainous  
features or headache at one time meets IHS criteria for migraine but it doesn’t meet criteria for 
new daily persistent headache or hemicrania continua and is not attributed  to another disorder.   
Our study is consistent with other studies showing high prevalence of psychiatric comorbidity in 
Transformed Migraine.15 Regardless of psychiatric comorbidity our patients severity and 
intensity of headache decreased by time as is indicated by Figure 3. Treatment outcome cannot 
be predicted based upon initial severity, depression, disability, or quality of life. 
We found no difference between drug-overusers and non overusers in outcome.16 As most of our 
patients were drug overusers and the mean duration of their analgesic overuse was several years. 
Their final assessment scores varies widely and many of them improved regardless of their acute 
drug use. 
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Overall disability, physical health and social functioning are more impaired in TM than in many 
other chronic illness.17,18 Our study showed some improvement in disability scores and total 
headache days which decreased from an average of 23.2 to 13.4 headache days per month. 
Patients still had 1/3 of the month with pain along with substantial social mal-functioning and 
physical ill health after 12months follow up. Previous studies using the SF-36 in headache 
patients, showed that patients with TM had the worst pain profile. SF-36 scale scores were most 
severely reduced in patients with TM, followed by CTTH and episodic migraine.19 Effective 
management of episodic migraine might prevent its progression to the more disabling TM.20 
Overall 86.6% of our TM patients had a coexisting psychiatric disorder this is similar to the  90% 
that Verri et al found. 21 Most common were adjustment disorders, Depression and generalized 
anxiety disorders (Fig 8)  
Overall outcome could not be predicted on initial severity and coexisting illnesses, but comorbid 
psychiatric diseases have important treatment implications. TM requires a combination of both 
pharmacological and behavioral treatment.22 Psychiatric comorbidity demands that a 
comprehensive treatment approach is needed. 
Depression can be a consequence of living with chronic, disabling headaches and may respond 
as headaches improve. However preexisting headache or anxiety may precipitate or exacerbate 
headache episodes in patients who are headache-prone. Headaches or affective distress may not 
improve until the comorbid psychopathology improves.23 Our study supports the view that 
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combined psychologic and pharmacologic treatment need to be considered.24,25 Relaxation or 
biofeedback training and short-term cognitive-behavioral therapy are particularly useful. 
Cognitive-behavioral headache treatment may include focused attention on the specific 
psychological problems that precipitate or exacerbate headache episodes or interfere with the 
treatment compliance. The role of antidepressants in chronic headache with comorbid psychiatric 
illness, is supported by several studies.26 We frequently use antidepressants combined with 
psychotherapies, such as stress management, behavior-relaxation therapy, biofeedback may be 
affective adjuvant treatment of transformed migraine. 
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Fig 1: Based on response criteria describes in methods, 29 subjects showed high response, 36 
intermediate response and 17 low response 
 
 
Number of Subjects
29
36
17
High Intermediate Low
C:\inetpub\wwwroot\results\230445-text.native.1292529880.doc 
Last printed 12/16/2010 12:06 PM Page 10 of 18 
FIGURE 2: Age can not predict outcome as patients with young age showed both type of 
response high as well as low and patients with middle age group had an intermediate response 
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FIGURE 3: The Kruskal-Wallis test for non-parametric analysis of this data demonstrated the highest 
change in headache severity index occurs with patients who had worst headache score at baseline 
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FIGURE 4: The Beck Depression Inventory (BDI) scores varied widely with an initial range of 
0-44, and it decreased gradually till six months then slightly increased at 12 months but all 
patients were still less than baseline. 
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FIGURE 5: Patients with low BDI score at baseline showed good response at outcome 
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FIGURE 6: SF-36 Results, SF-36 results showed a varied response among its various sub-
categories and was not a good predictor of outcome, but a good measurement of outcome. 
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FIGURE 7: The MIDAS scores were predominantly in Grade IV with 78% (n=58) scoring 
greater than 21 at the initial evaluation. The trend showed that a number of subjects improved to 
a Grade I-III at 3 and 6 months 
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FIGURE 8: seventy-two patients (88%) had at least one Axis I diagnosis. The most common 
diagnostic groups were Adjustment Disorder (n=35), Depression (n=22), and Generalized 
Anxiety Disorder GAD (n=14) 
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